223 related articles for article (PubMed ID: 38630384)
1. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
Kocher D; Cao L; Guiho R; Langhammer M; Lai YL; Becker P; Hamdi H; Friedel D; Selt F; Vonhören D; Zaman J; Valinciute G; Herter S; Picard D; Rettenmeier J; Maass KK; Pajtler KW; Remke M; von Deimling A; Pusch S; Pfister SM; Oehme I; Jones DTW; Halbach S; Brummer T; Martinez-Barbera JP; Witt O; Milde T; Sigaud R
J Neurooncol; 2024 Jun; 168(2):317-332. PubMed ID: 38630384
[TBL] [Abstract][Full Text] [Related]
2. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
3. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
[TBL] [Abstract][Full Text] [Related]
4. Combined BRAF
Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
[TBL] [Abstract][Full Text] [Related]
5. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
6. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
[TBL] [Abstract][Full Text] [Related]
8. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Sigaud R; Albert TK; Hess C; Hielscher T; Winkler N; Kocher D; Walter C; Münter D; Selt F; Usta D; Ecker J; Brentrup A; Hasselblatt M; Thomas C; Varghese J; Capper D; Thomale UW; Hernáiz Driever P; Simon M; Horn S; Herz NA; Koch A; Sahm F; Hamelmann S; Faria-Andrade A; Jabado N; Schuhmann MU; Schouten-van Meeteren AYN; Hoving E; Brummer T; van Tilburg CM; Pfister SM; Witt O; Jones DTW; Kerl K; Milde T
Nat Commun; 2023 Jul; 14(1):4533. PubMed ID: 37500667
[TBL] [Abstract][Full Text] [Related]
9. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T
Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790
[TBL] [Abstract][Full Text] [Related]
10. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Sander CA; Rush EA; Shi J; Arantes LMRB; Tesi RJ; Ross MA; Calderon MJ; Watkins SC; Kirkwood JM; Ferris RL; Butterfield LH; Vujanovic L
J Transl Med; 2022 Jul; 20(1):331. PubMed ID: 35879777
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
13. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
[TBL] [Abstract][Full Text] [Related]
14. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
15. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
16. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
17. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract][Full Text] [Related]
18. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
19. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
